期刊
TOXICOLOGIC PATHOLOGY
卷 46, 期 2, 页码 131-146出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/0192623317752101
关键词
immunotherapy; CAR T cells; TCR T cells; cancer; safety; cytokine release syndrome; neurotoxicity; gene modification; on-target toxicity; off-target toxicity
资金
- UK Government through Innovate UK
Gene-engineered T-cell therapies have the potential to revolutionize the treatment of cancer. These therapies have shown exceptional clinical efficacy specifically in the field of B-cell malignancies and the first products (Kymriah and Yescarta) have recently been approved in the United States for specific indications. The power of these treatments is also linked with a distinct set of toxicities both predicted and unpredicted, including off-tumor activity, cytokine release syndromes, and neurotoxicity, occasionally with fatal consequences. As these therapies begin to reach more patients, it is critical to develop the nonclinical tools to adequately determine the mechanisms driving these toxicities, to assess the safety risks of candidate products, and to develop strategies for safety management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据